American University Journal of Gender, Social Policy & the Law
Volume 23

Issue 4

Article 4

2015

High Times: Is The Federal Legalization of Marijuana Next? What
the Food and Drug Administration Could Learn from its Existing
Regulations
Christopher B. Erly
J.D. Candidate, 2016, American University Washington College of Law

Follow this and additional works at: https://digitalcommons.wcl.american.edu/jgspl
Part of the Criminal Law Commons, Criminology and Criminal Justice Commons, Food and Drug Law
Commons, Health Policy Commons, and the Public Policy Commons

Recommended Citation
Erly, Christopher B. (2015) "High Times: Is The Federal Legalization of Marijuana Next? What the Food and
Drug Administration Could Learn from its Existing Regulations," American University Journal of Gender,
Social Policy & the Law: Vol. 23 : Iss. 4 , Article 4.
Available at: https://digitalcommons.wcl.american.edu/jgspl/vol23/iss4/4

This Article is brought to you for free and open access by the Washington College of Law Journals & Law Reviews
at Digital Commons @ American University Washington College of Law. It has been accepted for inclusion in
American University Journal of Gender, Social Policy & the Law by an authorized editor of Digital Commons @
American University Washington College of Law. For more information, please contact kclay@wcl.american.edu.

High Times: Is The Federal Legalization of Marijuana Next? What the Food and
Drug Administration Could Learn from its Existing Regulations
Cover Page Footnote
J.D. Candidate, 2016, American University Washington College of Law; B.A., Dickinson College . I would
like to thank Professor Lewis Grossman for his invaluable guidance and insight. Any errors are the
author’s and the author’s alone.

This article is available in American University Journal of Gender, Social Policy & the Law:
https://digitalcommons.wcl.american.edu/jgspl/vol23/iss4/4

Erly: High Times: Is The Federal Legalization of Marijuana Next?

HIGH TIMES: IS THE FEDERAL
LEGALIZATION OF MARIJUANA NEXT?
WHAT THE FOOD AND DRUG
ADMINISTRATION COULD LEARN
FROM ITS EXISTING REGULATIONS
CHRISTOPHER B. ERLY
I.Introduction .............................................................................................660
II.Background ............................................................................................662
A. The FDCA Gives the FDA Vast Regulatory Authority over
Food, Drugs, Biologics, Dietary Supplements, Tobacco,
and Medical Devices ...............................................................662
1. Defining “Drug” ................................................................662
2. Defining “New Drug” ........................................................663
3. The NDA Process ..............................................................663
4. The FDCA Gives the FDA Authority to Regulate
Tobacco Products...............................................................666
III.Analysis ................................................................................................668
A. Marijuana Could Not Be Regulated as a Drug Because the
FDA Would Not Approve an NDA Proposing Marijuana
Be Used for a Medical Purpose ............................................668
1. Marijuana Fits Firmly into the FDCA’s Definition of
a Drug, Which Would Require Marijuana Be
Regulated Under the “Drug” Statutes ................................668
2. Marijuana Is a “New Drug” Because It Lacks an
Approved NDA ..................................................................669
3. Marijuana Would Likely Not Be Approved in the NDA
Process Because as a Botanical Drug It Is Difficult to
Standardize Marijuana to Ensure Consistent Dosing
and Active Constituents .....................................................670
a. IND Approval for Phase I and Phase II Studies ..........671
 J.D. Candidate, 2016, American University Washington College of Law; B.A.,
Dickinson College . I would like to thank Professor Lewis Grossman for his invaluable
guidance and insight. Any errors are the author’s and the author’s alone.

659

Published by Digital Commons @ American University Washington College of Law, 2015

1

American University Journal of Gender, Social Policy & the Law, Vol. 23, Iss. 4 [2015], Art. 4

660

JOURNAL OF GENDER, SOCIAL POLICY & THE LAW

[Vol. 23:4

b. IND Approval for Phase III Studies ............................674
c. NDA Review ...............................................................676
B. Marijuana Regulated Under the Tobacco Provisions of the
FDCA ......................................................................................677
1. Premarket Approval for “New Tobacco Products”
Could Not Be Used to Regulate New Marijuana
Products Because the Analysis Is based on Previously
Marketed Products .............................................................680
IV.Conclusion ............................................................................................682

I.

INTRODUCTION

The majority of Americans support the legalization of marijuana,
suggesting that future policy will reflect the views of the democratic
majority.1 Polls show that the support of legalizing marijuana is increasing
over time.2 The upward trend of Americans favoring legalization is not a
recent phenomenon, but a trend that has grown steadily since 1985.3 The
substantial increase in political support for legalizing marijuana does not
match the minute increase of marijuana users in the United States.4 There
has only been a 5% increase in Americans’ usage of marijuana since 1985,
which was the turning point of the upward trend in favoring the legalization
of marijuana.5 A 5% increase in marijuana use does not explain a 35%
change in support for legalization.6 Indeed, national polls show that public
support for the legalization of marijuana is ahead of most elected officials’
support.7 Nonetheless, marijuana policy reform is occurring throughout the
United States.8
1. See Art Swift, For First Time, Americans Favor Legalizing Marijuana,
GALLUP (Oct. 22, 2013), http://www.gallup.com/poll/165539/first-time-americansfavor-legalizing-marijuana.aspx (finding that 58% of Americans favor legalizing
marijuana).
2. See id. (illustrating that support for legalizing of marijuana has risen from 12%
since 1969 to 58% as of 2013).
3. See id. (showing that 23% of Americans favored legalization of marijuana in
1985).
4. See Lydia Saad, In U.S., 38% Have Tried Marijuana, Little Changed Since
‘80s, GALLUP (Aug. 2, 2013), http://www.gallup.com/poll/163835/tried-marijuanalittle-changed-80s.aspx; Swift, supra note 1.
5. See Saad, supra note 4 (displaying marijuana usage change from 33% to 38%
between 1985 and 2013).
6. See id.; Swift, supra note 1.
7. See MARIJUANA POLICY PROJECT, SUPPORT FOR MARIJUANA POLICY REFORM 1
(2014) available at http://www.mpp.org/assets/pdfs/library/State-Polling.pdf.
8. See State Marijuana Laws Map, GOVERNING, http://www.governing.com/gov-
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Currently, twenty-three states and the District of Columbia have
legalized possession of marijuana in some form.9 As of November 2014,
Alaska, Oregon, and the District of Columbia have pushed their
legalization efforts beyond medicinal use joining Colorado and Washington
in legalizing marijuana for recreational use.10 The District of Columbia’s
recreational marijuana initiative, Initiative 71, took effect on February 26,
2015.11 Colorado is collecting millions of dollars per month in revenue
from marijuana taxes, fees, and licensing, which may encourage states that
have legalized medicinal marijuana to legalize recreational marijuana.12
Indeed, 2014 was a substantial year for marijuana legalization efforts.13
However, analysts suggest that multiple more state ballot initiatives are
likely to follow in the coming years, which could make the legalization of
marijuana a platform issue in the 2016 presidential election.14
This Comment argues that marijuana could not be regulated under the
Food and Drug Administration (FDA) drug regime easily, and would rather
be best regulated under a new Food, Drug, and Cosmetic Act (FDCA)
statutory section resembling the FDCA’s tobacco section. Part II examines
the FDA’s regulatory models that could be used to regulate marijuana.15
Part III applies marijuana to existing regulatory models.16 Part IV
data/state-marijuana-laws-map-medical-recreational.html (last visited Nov. 9, 2014)
[hereinafter Marijuana Map] (discussing the fact that November 2014 elections
resulted in Alaska, Oregon, and District of Columbia legalizing recreational
marijuana).
9. Id.
10. See id.
11. See id. (comparing the 2014 ballot initiatives to Colorado and Washington’s
ballot initiatives legalizing recreational marijuana in 2012); Press Release, Marijuana
Prohibition Ends in DC as Initiative 71 Takes Effect, DCMJ (Feb. 26, 2015), available
at
http://dcmj.org/press-release-marijuana-prohibition-ends-dc-initiative-71-takeseffect/.
12. See Colorado Marijuana Tax Data, COLORADO DEPT. OF REVENUE,
https://www.colorado.gov/pacific/sites/default/files/0215%20Marijuana%20Tax%2C%
20License%2C%20and%20Fees%20Report.pdf (last visited May 8, 2015) (reporting
$9 million in state revenue from marijuana for March 2015).
13. See Marijuana Map, supra note 8 (explaining that the number of states
legalizing recreational marijuana doubled in 2014).
14. See Nick Wing, These States Are Most Likely To Legalize Next. Will You Have
A Happier 4/20 In 2015?, HUFFINGTON POST (Apr. 18, 2014),
http://www.huffingtonpost.com/2014/04/18/states-legalize-weed_n_5162737.html (last
updated Apr. 23, 2014).
15. See infra Part II (outlining the FDA’s regulatory scheme of drugs and
tobacco).
16. See infra Part III (analyzing marijuana regulation under the FDCA’s drug
section and tobacco section).
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concludes that marijuana has the potential to be regulated under either a
drug model or tobacco model, but that the tobacco model is preferable
because of its ability to incorporate the recreational use of marijuana and its
lack of standardization.17
II. BACKGROUND
A. The FDCA Gives the FDA Vast Regulatory Authority over Food,
Drugs, Biologics, Dietary Supplements, Tobacco, and Medical Devices
The FDCA empowers the FDA to exercise national authority in
regulating food (including dietary supplements), drugs, medical devices,
tobacco, cosmetics, and biologics.18 In giving the FDA broad regulatory
power with regards to these categories, Congress intended to provide the
FDA with federally mandated authority.19 The FDA is responsible for
making sure that the regulatory schemes constructed by the FDCA are
followed, which first requires the product in question be classified under
one of the FDCA’s definitions such as a cosmetic or supplement.20 After
the product is classified, it is regulated under the product’s corresponding
section in the FDCA.21
1.

Defining “Drug”

Congress enacted the FDCA with the intention of it being liberally
construed and interpreted “as broad as its literal language indicates.”22 The
FDCA defines “drug” as:
(A) articles recognized in the official United States Pharmacopœia,
official Homœopathic Pharmacopœia of the United States, or official
National Formulary, or any supplement to any of them; and (B) articles
intended for use in the diagnosis, cure, mitigation, treatment, or
prevention of disease in man or other animals; and (C) articles (other
than food) intended to affect the structure or any function of the body of
17. See infra Part IV (concluding that federal regulation of marijuana is coming
and its regulation will look more like a tobacco regime than a drug regime).
18. See generally 21 U.S.C. §§ 301-399f (2012) (containing all statutory
previsions giving FDA regulatory authority).
19. See What does FDA Do?, FDA, http://www.fda.gov/aboutfda/transparency/
basics/ucm194877.htm (last visited Oct. 20, 2014).
20. See § 321 (providing various definitions of products that fall within the FDA’s
regulatory authority).
21. See, e.g., §§ 341-50 (regulating food); §§ 351-60 (regulating drugs and
devices); § 387 (regulating tobacco).
22. See United States v. Bacto-Unidisk, 394 U.S. 784, 798 (1969) (stating that
definition of “drug” within FDCA was meant to be broadly interpreted).
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However, even if a product is not specifically intended to diagnose, cure,
mitigate, treat, or prevent a disease; if the manufacturer makes a claim that
its product can diagnose, cure, mitigate, treat or prevent a disease, then the
product would be construed as a drug by the FDA.24
2.

Defining “New Drug”

Once a product is determined to be a “drug,” one would have to consider
whether it is a “new drug.”25 A drug is considered a new drug if it is not
generally recognized by scientific experts as safe and effective for its
intended use.26 New drugs are prohibited from being introduced into
commerce until they are deemed safe and effective.27 The FDA interprets
the FDCA to mean that a drug is not generally recognized as safe and
effective, and thus a “new drug,” if it is marketed without an FDAapproved New Drug Application (NDA).28 The Supreme Court affirmed
this interpretation of the FDCA and has held that without an approved
NDA a drug cannot be generally recognized as safe and effective, no matter
the validity of the claim.29 Minus a few narrow exceptions, an approved
NDA is a required part of a drug being recognized as safe and effective in
the United States.30
3.

The NDA Process
Prior to submitting an NDA, the sponsor of the NDA must submit an
23. See § 321(g)(1).
24. See, e.g., General Mills, Inc. Warning Letter, FDA (May 5, 2009), available at

http://www.fda.gov/iceci/enforcementactions/warningletters/2009/ucm162943.htm
(warning the makers of Cheerios® Toasted Whole Grain Oat Cereal that its health
claims regarding Cheerios® reducing cholesterol made Cheerios® an unapproved new
drug).
25. See § 321(p)(1) (requiring a product to first be a drug as defined by the FDCA,
before considering whether the FDA has approved the product).
26. See id.
27. See § 355(a) (“No person shall introduce or deliver for introduction into
interstate commerce any new drug, unless an approval of an application filed. . .”).
28. See Weinberger v. Hynson, 412 U.S. 609, 629 (1973).
29. See id. (holding “the hurdle of ‘general recognition’ of effectiveness requires
at least ‘substantial evidence’ of effectiveness for approval of an NDA.”).
30. See New Drug Application, FDA, http://www.fda.gov/drugs/develo
pmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/newdr
ugapplicationnda/default.htm (last visited Nov. 9, 2014) (stating that every new drug
since 1938 has been subject to an approved NDA before United States
commercialization).
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Investigational New Drug Application (IND), which primarily focuses on
development of the drug’s pharmacological profile and determination of its
toxicity.31 The IND must demonstrate that the drug product is safe for
testing in humans and that the clinical protocol is properly designed for its
intended objectives.32 The IND requires a description of the proposed
clinical studies (to assure studies would be acceptable for NDA
consideration); product chemistry, manufacturing, and controls data
(CMC); as well as summaries of the toxicological effects and biological
disposition of the drug in animals and, if known, in humans (including nonclinical data and data from foreign studies).33
After the FDA is satisfied with the sponsor’s IND, the sponsor will begin
Phase I clinical studies.34 Phase I typically involves using a small
volunteer group to determine metabolic and pharmacological actions
associated with increasing doses allowing for preliminary evidence of the
drug’s effects.35 Once Phase I is concluded, Phase II begins with clinical
studies composed of larger subject groups, which now include subjects
with the condition that the drug is proposed to treat.36 The sponsor begins
to collect preliminary data on effectiveness of the drug by looking at
biological evidence that the drug is doing what it is supposed to do, while
still examining the safety of the drug.37 If the drug is still producing
evidence of effectiveness, and the adverse effects are tolerable, FDA allows
the sponsor to move on to Phase III clinical studies.38 Phase III studies are
31. See 21 C.F.R. § 312.21.
32. See id. § 312.22 (stating the general principles of IND); IND Application

Reporting:
Protocol
Amendments,
FDA,
http://www.
fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/A
pprovalApplications/InvestigationalNewDrugINDApplication/ucm362503.htm
(last
visited Dec. 5, 2014) (allowing sponsor to progress from Phase I to Phase II to Phase
III by submitting “protocol amendments” instead of a new IND for each phase).
33. See § 312.23 (describing the contents required in IND); GUIDANCE FOR
INDUSTRY BOTANICAL DRUG PRODUCTS 7, 18, FDA (June 2004) [hereinafter
BOTANICAL
GUIDANCE]
available
at
http://www.fda.
gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm07049
1.pdf.
34. See § 312.2 (requiring approval of IND application before clinical testing can
begin).
35. See The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective,
FDA, http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm (last
visited on Oct. 18, 2014) [hereinafter Drug Review Process] (providing that Phase I
testing groups are generally 20 to 80 subjects).
36. See id. (explaining Phase II groups have 100 to 300 subjects).
37. See id.
38. See id. (stating that effectiveness must be shown in Phase II trials before a drug
sponsor may move on to Phase III trials).
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typically expensive multi-year studies involving thousands of subjects with
the sponsor studying different doses and population groups.39 After many
years of research and, often the expenditure of more than a billion dollars,
the sponsor can submit an NDA to the FDA to determine whether the drug
will be marketable.40
NDA regulations require the sponsor to provide the FDA with in-depth
information regarding the drug, which includes the drug’s components,
dosages, proposed labeling, and full reports of investigations into whether
the drug is safe and effective.41 The FDA will withhold approval of a new
drug unless the sponsor provides substantial evidence that the drug will
have the effect it purports to have under conditions of use prescribed,
recommended, or suggested on the labeling.42 An NDA must contain
substantial evidence of effectiveness derived from adequate and wellcontrolled clinical studies, evidence of safety, and adequate information of
the product’s CMC, all submitted in the format that the FDA requires.43
The FDA will approve the drug for sale if, after evaluation, the FDA
determines that the drug’s benefits outweigh its risks.44
However, even after approval of an NDA, the FDA monitors adverse
event reports involving the approved drug, which could result in the drug
being removed from the market if an unforeseen risk arises.45 Additionally,
drug approval may be contingent on the sponsor’s inclusion of a voluntary
39. See id. (explaining Phase III clinical studies generally range from a few
hundred to 3,000 participants); see also Martin S. Lipsky & Lisa K. Sharp, From Idea
to
Market:
The
Drug
Approval
Process,
MEDSCAPE
(2001),
http://www.medscape.com/viewarticle/405869_1 (estimating 10% of medication fail in
Phase III trials).
40. See Matthew Herper, The Truly Staggering Cost of Inventing New Drugs,
FORBES
(Feb.
10,
2012,
7:41
AM),
http://www.forbes.com/sites
/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventing-new-drugs/ (finding
that the average cost of bringing a drug to market is $1.3 billion).
41. See 21 U.S.C § 355(b) (providing a detailed list of the contents that the drug
sponsor is responsible for providing within the NDA).
42. See id. §355(d) (providing a detailed list of factors that can result in approval
being withheld besides general safety and effectiveness data, including lack of patent
information and manufacturing details).
43. See id. § 355 (providing the less specific statutory requirements required by
Congress); 21 C.F.R. part 314.50 (providing regulations promulgated by FDA
concerning a NDA’s content and format requirements, which is much more specific
than what was originally provided by FDCA).
44. See How FDA Evaluates Regulated Products: Drugs, FDA,
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm269834.htm (last visited Oct.
18, 2014).
45. See id. (describing the MedWatch database used to catalog adverse events
involving drugs).
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or involuntary restriction, or on the contingency that the sponsor continues
Phase IV clinical studies after approval for further data.46
4.

The FDCA Gives the FDA Authority to Regulate Tobacco Products

The FDA’s regulatory authority is vast reaching beyond the regulation of
drugs to include such products as tobacco.47 In 2009, Congress passed the
Family Smoking Prevention and Tobacco Control Act (TCA) giving the
FDA authority to regulate the manufacturing, marketing, and sale of
tobacco products.48 Congress enacted TCA with the understanding that
tobacco is a legal product that poses some health risks and is only for
adults.49 However, the FDA does not regulate tobacco like drugs under the
strict safe and effective standard, but instead regulates tobacco under the
new standard of “appropriate for the protection of the public health.”50
The TCA creates multiple restrictions on the sale of tobacco: the
purchaser must be at least eighteen years of age, purchases of tobacco
products must be made face-to-face, and purchases are limited by
quantity.51 Tobacco advertisements have extensive regulations, which
attempt to eliminate any advertisements directed toward those under
eighteen years of age.52 Additionally, tobacco products are misbranded if
packaging makes unapproved “reduced harm” claims or the warning labels
do not follow the specific visibility requirements.53 Regulations require
46. See Food and Drug Administration Amendments of 2007, Pub. L. No. 110–
85,121 Stat 922 (authorizing Risk Evaluation and Mitigation Strategies (REMS) post
NDA approval, which provides that the FDA may require the drug sponsor to take
additional actions regarding the labeling or dispensing of its drug in order to minimize
potential risks).
47. See generally 21 U.S.C. § 387 (2012) (providing the statutory framework for
FDA’s regulation over tobacco).
48. See generally Family Smoking Prevention and Tobacco Control and Federal
Retirement Reform, Pub. L. No. 111-31, 123 Stat 1776.
49. See Overview of the Family Smoking Prevention and Tobacco Control Act,
FDA
[hereinafter
TCA
Overview],
http://www.fda.go
v/downloads/TobaccoProducts/GuidanceComplianceRegulatoryInformation/UCM3369
40.pdf (last visited Oct. 19, 2014) (recognizing a goal of tobacco regulation is to
prevent those under eighteen from using an addictive and potentially harmful substance
before fully understanding the consequences).
50. See § 387f (authorizing Secretary to promulgate rules appropriate for the
protection of the public health).
51. See TCA Overview, supra note 49.
52. See, e.g., id. (banning tobacco advertisements within 1,000 feet of a school or
playground, as well as banning tobacco advertisement from sporting and entertainment
events).
53. See § 387c (providing that any tobacco product that does not comply with all
labeling regulations may be misbranded); § 387k (restricting the use of “reduced risk”
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tobacco manufactures to register with the FDA and be subject to
inspections.54 Further, the tobacco industry must disclose all research on
health, toxicological, behavioral, or physiologic effects of tobacco use. 55
The FDA may implement standards for tobacco products to regulate such
things as nicotine levels, pesticide use, and manufactures discloser of all
tobacco product components.56 Additionally, if the product contains an
extraneous component that is harmful it is adulterated, and the FDA may
seize it.57 Pre-market review may also be required for new tobacco
products if they present a significant variation from currently marketed
tobacco products.58 Manufacturers of all new tobacco products must file a
substantial equivalence report with the FDA, and the new tobacco products
can be legally marketed without premarket review only if the FDA
determines the new products are substantially equivalent to a predicate
tobacco product.59
However, while the TCA provides the FDA with significant regulatory
power over tobacco, there are still restraints on the FDA’s authority over
tobacco.60 The FDA cannot ban certain classes of tobacco products,
require zero nicotine, require prescriptions to purchase tobacco, establish a
minimum age older than 18 years old, or ban face-to-face sales in any
particular category of retail outlets.61
terms on labeling, such as light, low, or mild); § 387h (extending FDA recall authority
to misbranded or adulterated products).
54. See § 387e (listing specific annual registration requirements for tobacco
manufacturers, including facilities and products).
55. See § 387d (b) (requiring data submissions relating to research activities of
tobacco manufacturer); § 387e (listing specific annual registration requirements for
tobacco manufacturers, including facilities and products); § 387i (requiring
manufacturers to keep specified records, which Secretary may request).
56. See § 387d (a)(1) (requiring disclosure of tobacco product compounds); § 387g
(banning the use of artificial or natural flavors as a component of cigarettes; requiring
tobacco producer to abide by set pesticide levels).
57. See § 387b (defining adulterated tobacco products as those that are filthy,
poisonous, and/or deleterious); § 387h (extending FDA recall authority to adulterated
products).
58. See § 387j (requiring an application attesting that the new tobacco product has
the same characteristics as a predicate tobacco product, or provide clinical data to
support differing characteristics pose no threat to public health).
59. See id. (defining “predicate tobacco product” as a tobacco product that was
commercially marketed (other than in a test market) as of February 15, 2007, or a
product previously found to be substantially equivalent by the FDA and in compliance
with the requirements of the FDCA).
60. See generally §§ 387f (d), 387g (d).
61. See §§ 387f (d), 387g (d) (providing safeguards to insure at least a minimum
level of access to standard tobacco products).
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Tobacco presents addictive and dangerous qualities, which, surprisingly,
has only brought it under the FDA’s regulation relatively recently.62
Tobacco has a long history in the United States: economic forces coupled
with consumer needs provided the tobacco industry with political influence
and the ability to silence the anti-tobacco movements.63 Scientific findings
and political leadership led to the tobacco industry’s objection to regulation
and liability.64
III. ANALYSIS
A. Marijuana Could Not Be Regulated as a Drug Because the FDA
Would Not Approve an NDA Proposing Marijuana Be Used for a Medical
Purpose
As a botanical product, marijuana faces a variety of challenges regarding
standardization and CMC data that regular synthetic or highly purified
drugs do not encounter because they are created in a lab versus grown from
the ground.65 Currently, only two botanical drug products have met the
strict NDA requirements and received FDA approval.66
1. Marijuana Fits Firmly into the FDCA’s Definition of a Drug, Which
Would Require Marijuana Be Regulated Under the “Drug” Statutes
Without a federal statute expressly defining marijuana as something
other than a drug, marijuana squarely fits within the FDCA’s definition of a
drug.67
FDCA defines “drug” as any article listed in a major
62. See TCA Overview, supra note 49 (discussing 2009 amendment allowing FDA
regulation of tobacco products).
63. See Paul Verkuil, “A Leadership Case Study of Tobacco and its Regulation”,
PUBLIC TALK, http://www.upenn.edu/pnc/ptverkuil.html (last visited Nov. 15, 2014)
(explaining first anti-tobacco movements began in 1604, but were overcame by profit
motives).
64. See id. (discussing the Clinton Administrations involvement in warning the
public of tobacco’s health risks, which helped decrease tobacco industry’s political
power).
65. See BOTANICAL GUIDANCE, supra note 33, at 2, 5 (defining “botanical
product” for purposes of FDA guidance and discussing possible issues within drug
approval process).
66. FDA approves first anti-diarrheal drug for HIV/AIDS patients, FDA,
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333701.htm
(last visited Oct. 19, 2014) (stating that the FDA has only approved two botanical
drugs, Fulyzaq in 2012 and Veregen in 2006).
67. See generally 21 U.S.C. §§ 351-361 (2012) (creating the regulatory framework
for drugs and devices).
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pharmaceutical compendium, intended to treat, mitigate, or diagnose a
medical condition; or is intended to affect the structure or function of its
consumer.68 The United States Pharmacopeia (USP) and the National
Formulary (NF) both listed marijuana in their publications from 1850 until
1942, at which time marijuana was prescribed for various conditions
including labor pains, nausea, and rheumatism.69 Today, the use of medical
marijuana is recognized in multiple states, allowing the medicinal use of
marijuana for treating Alzheimer’s disease, anorexia, AIDS, arthritis,
cachexia, cancer, Crohn’s disease, epilepsy, glaucoma, HIV, migraines,
multiple sclerosis, nausea, pain, spasticity, and wasting syndrome. 70
Additionally, marijuana is commonly smoked by users for its stimulating
effect on the brain causing the release of dopamine, which produces a
euphoric sensation, or “high.”71 Marijuana’s prescribed use for treating
diseases and conditions, and its effect on the brain’s function clearly make
marijuana a “drug” as defined by the FDCA.72
2.

Marijuana Is a “New Drug” Because It Lacks an Approved NDA

Marijuana’s inclusion in the broadly defined drug category does not
automatically require preapproval before marketing; however, it does make
marijuana subject to a “new drug” analysis, which requires premarket
approval if the article is a new drug.73 Not only is marijuana a “drug,” but
it is also a “new drug.”74 Marijuana is a new drug because it is not
68. See § 321(g)(1); Lewis A. Grossman, Food, Drugs, and Droods: A Historical
Consideration of Definitions and Categories in American Food and Drug Law, 93
CORNELL L. REV. 1091, 1127 (July 2008) (stating that, despite the language of the
FDCA, the FDA and the courts do not regard inclusion of a substance in the compendia
as in and of itself sufficient for drug classification).
69. See Gerald Gianutsos, Medical Marijuana: Therapeutic Uses and Legal Status,
US
PHARMACIST
(Oct.
1,
2010),
http://www.uspharmacist.com
/continuing_education/ceviewtest/lessonid/106975/ (stating marijuana has been
cultivated in the United States since 1611).
70. See UNITED STATES GENERAL ACCOUNTING OFFICE, MARIJUANA EARLY
EXPERIENCES WITH FOUR STATES’ LAWS THAT ALLOW USE FOR MEDICAL PURPOSES,
51-53 (2002), available at http://www.gao.gov/assets/240/236305.pdf.
71. See How does marijuana produce its effects?, NAT’L INST. ON DRUG ABUSE,
http://www.drugabuse.gov/publications/research-reports/marijuana/how-doesmarijuana-produce-its-effects (last viewed May 12, 2014).
72. See id. (discussing marijuana’s effects on brains regulation of balance, posture,
coordination, and reaction time).
73. See 21 C.F.R. § 310.100 (2014) (explaining that some drugs marketed before
1938 are covered under a grandfather clause allowing those drugs to be marketed
without premarket approval as long as drug has not changed in formulation,
manufacture control, or labeling in a way that may significantly affect safety of drug).
74. See generally 21 U.S.C. § 355 (2012) (proving the statutory regulations for
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generally recognized by scientific experts as safe and effective for use
under the conditions prescribed or recommended.75 Without having been
deemed safe and effective, “new drugs” are prohibited from being
introduced into commerce.76 While marijuana has been in society and used
medicinally for a long time, the FDA states that a drug is a “new drug” if
marketed without an FDA approved New Drug Application (NDA), and
marijuana has no uses that have been approved through the NDA process.77
Currently, the FDA’s position on the medicinal use of marijuana is clear; it
explicitly concluded in 2011 that marijuana has a high potential for abuse,
is not currently recognized for medical use, and is unsafe to use under
medical supervision.78 Marijuana has not been subjected to the NDA
process, nor has it been generally recognized as safe and effective for
treating and conditions, so it is a “new drug” under the FDCA that would
be illegal to sell.79
3. Marijuana Would Likely Not Be Approved in the NDA Process
Because as a Botanical Drug It Is Difficult to Standardize Marijuana to
Ensure Consistent Dosing and Active Constituents
For marijuana to become recognized as safe and effective for a particular
use, FDA would have to approve a New Drug Application (NDA)
proposing marijuana be used to treat a specific condition or disease.80 An
NDA requires the sponsor to provide the FDA with in-depth information
regarding the drug, including the drug’s components, dosages, proposed
labeling, and full reports of investigations into whether the drug is safe and
effective.81 The FDA will withhold approval of a new drug unless the
sponsor provides substantial evidence that the drug will have the effect it
purports to have under conditions of use prescribed, recommended, or

new drugs).
75. See id. § 321(p)(1) (defining “new drug”).
76. See id. § 355(a) (“No person shall introduce or deliver for introduction into
interstate commerce any new drug,” unless the new drug’s NDA has been approved).
77. See
FDA
and
Marijuana,
FDA,
http://www.fda.gov/NewsEvents/PublicHealthFocus/ucm421163.htm (last visited May
8, 2015) [hereinafter FDA and Marijuana] (stating that “FDA has not approved
marijuana as a safe and effective drug for any indication.”).
78. See 76 Fed. Reg. 40552 (July 8, 2011) (denying petition to reschedule
marijuana).
79. See § 321(p)(1) (stating that a drug is a new drug is not generally recognized as
safe and effective among experts); FDA and Marijuana, supra note 96 (stating that
marijuana has not been generally recognized as safe and effective among experts).
80. See § 355(b) (requiring an NDA to provide reports of the drugs effective use).
81. See id.
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suggested on the labeling.82 As discussed above, substantial evidence of
effectiveness and safety ordinarily must be proven by three stages of wellcontrolled clinical studies.83
a.

IND Approval for Phase I and Phase II Studies

Before marijuana could be tested in clinical studies, the sponsor would
have to submit an IND providing an overview of marijuana’s chemical
constituents, manufacturing and processing, safety data, and details on the
proposed clinical studies.84 Providing marijuana’s chemical constituents
would be the first difficulty when submitting an IND because scientists
continue to have difficulty identifying some of the hundreds of chemical
constituents in.85 In a guidance document, however, the FDA has
recognized that in many cases the active constituent in a botanical drug is
not identified, nor is its biological activity well characterized, and thus has
suggested that active constituents need not be completely identified during
the IND process.86
Nevertheless, the FDA would evaluate other factors of the IND more
critically because of the lack of knowledge concerning marijuana’s active
constituents.87 The FDA’s general guidance on botanicals, as applied to
marijuana, suggest a combination of tests and controls would need to be
implemented in order to ensure the identity, purity, quality, strength,
potency, and consistency of marijuana.88 The manufacturing process will
need to be well-defined within the CMC portion of the IND including

82. See § 355(d)-(e) (stating NDA approval will be withdrawn upon finding
imminent hazard to public health).
83. See Drug Review Process, supra note 35 (overviewing FDA’s drug review
process: animal testing, IND, Phase I–III testing, review meeting, NDA submission,
NDA review).
84. See id.; 21 C.F.R. § 312.22 (2014) (stating that IND must contain sufficient
information to demonstrate that drug product is safe for testing in humans and that
clinical protocol is properly designed for its intended objectives).
85. What Chemicals Are in Marijuana and Its Byproducts?, PROCON,
http://medicalmarijuana.procon.org/view.answers.php?questionID=636 (last updated
Aug. 8, 2009, 6:11 PM) (discussing composition of marijuana and difficulties with
determining all of its compounds).
86. See BOTANICAL GUIDANCE, supra note 33, at 5 (suggesting that constituents do
not need to be fully identified during IND, but will need to be further identified for
ultimate NDA approval).
87. See id. (suggesting more stringent manufacturing controls to insure consistent
product is constituents cannot be identified).
88. See id. (including (1) multiple tests for drug substance and drug product, (2)
raw material and process controls, and (3) process validation).
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adequate in-process controls.89
Consistency could be the biggest challenge because variations in soil,
geographical region, water, light, harvesting, and storage condition
magnify the inconstant chemical makeup of marijuana and make marijuana
standardization nearly impossible.90 If the drug sponsor cannot show the
ability to consistently produce a single formulation and dose of marijuana
from batch-to-batch the FDA would likely deny the NDA because
inconsistencies between batches would cause uninterpretable results in the
clinical trial.91 IND approval only permits the drug sponsor to conduct
clinical trials with the new drug, which will provide the data that is
ultimately submitted for NDA consideration.92 If the clinical trials do not
conform to clinical standards the FDA will likely deny the drug sponsors
NDA because the results of the studies are not credible.93 The dosage and
composition of the marijuana will be very important during clinical trials to
ensure credible results for the NDA.94 However, marijuana plants do not
need to be produced perfectly identical.95 “Different plant strains and
batches vary radically in their levels of psychoactive substances and in the
contaminants — fungi, bacteria, pesticides, heavy metals and other
substances — they contain.”96 The drug sponsor must state in the IND how
it would control all of these factors in order to produce a standardized
product.97 Although lack of standardization would not prevent approval of
the IND for initial clinical trials, it could hinder IND proposals for Phase

89. See § 312.23(a)(7)(iv).
90. See Claire Frezza, Medical Marijuana: A Drug Without A Medical Model, 101

Geo. L.J. 1117, 1135 (2013) (quoting Suzanne D. McGuire, Comment, Medical
Marijuana: State Law Undermines Federal Marijuana Policy—Is the Establishment
Going to Pot?, 7 SAN JOAQUIN AGRIC. L. REV. 73, 74-75 (1997)).
91. See BOTANICAL GUIDANCE, supra note 33, at 11-12 (recommending the
sponsor outline its ability to produce batch-to-batch consistency within the CMC data).
92. See Drug Review Process, supra note 35.
93. See generally § 314.125 (stating reasons for NDA refusal, including,
inadequate methods for controls).
94. See BOTANICAL GUIDANCE, supra note 33, at 11-12 (recommending a single
formulation and a single dosage form be used throughout different states of the clinical
trials unless impossible).
95. See id. (suggesting samples be retained from Phase I and Phase II trials for
product comparison with the product used in Phase III trials to ensure batch
consistency).
96. See Henry I. Miller, The Real Dope On Medical Marijuana, FORBES (Mar. 28,
2012, 10:56 AM), http://www.forbes.com/sites/henrymiller/2012/03/28/the-real-dopeon-medical-marijuana/.
97. See BOTANICAL GUIDANCE, supra note 33, at 10-12 (discussing CMC
requirements of § 312.23(a)(7)).
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III clinical studies and, ultimately, the approval of its NDA. 98
Showing that marijuana can be standardized through testing and controls
is important for IND approval, but a showing that marijuana is safe for
human studies is more important.99 The drug sponsor must provide
pharmacological and toxicological information within the IND.100 The
proposed dose of marijuana to be tested must be shown to be safe through
clinical and nonclinical data, which may include studies not conducted by
the sponsor (e.g. foreign studies).101 The sufficiency of data required for
Phase I and Phase II testing is relatively low compared to what is necessary
for Phase III testing.102
Moreover, the extensive use of marijuana in humans already may
provide sufficient information to support initial clinical studies, forgoing
the standard in vivo or in vitro experiments testing articles under laboratory
conditions which the FDA generally requires.103 Currently, there are a
variety of peer-reviewed studies weighing in on the safety and efficacy of
marijuana that provide data for the FDA’s consideration.104 Arguably, the
largest safety concern of marijuana is the delivery method: smoking
presents issues of pulmonary disease and lung cancer.105 The safety of

98. See 21 U.S.C. §355(d) (2012) (requiring NDA to contain substantial evidence
of effectiveness derived from adequate and well-controlled clinical studies);
BOTANICAL GUIDANCE, supra note 33, at 11-12 (explaining the importance of product
consistency for Phase III trials).
99. See 21 C.F.R. §312.22 (2014) (requiring IND to contain sufficient information
to demonstrate that drug product is safe for testing in humans).
100. See id. § 312.23(a)(8) (describing content and format of pharmacological and
toxicological information to be provided in IND).
101. See BOTANICAL GUIDANCE, supra note 33, at 13 (stating less safety data is
necessary for initial clinical trials then what is expected from by synthetic or highly
purified drugs).
102. See id.; Drug Review Process, supra note 35 (explaining that Phase I testing is
used to determine safety and side effects on healthy individuals).
103. See BOTANICAL GUIDANCE, supra note 33, at 25-26 (comparing herbal
products with extensive human use that require less safety testing to synthetic drugs
with little to no human use that require more extensive nonclinical safety testing).
104. See
60
Peer-Reviewed
Studies
on
Marijuana,
PROCON,
http://medicalmarijuana.procon.org/view.resource.php?resourceID=000884
(last
updated Feb. 27, 2015) (providing medical studies involving cannabis and cannabis
extracts, from 1990-2014).
105. See Jenny Hope, Cannabis ‘kills 30,000 a year’, DAILY MAIL,
http://www.dailymail.co.uk/health/article-179264/Cannabis-kills-30-000-year.html
(last visited Oct. 24, 2014) (speculating that marijuana smokers suffer from lung
disease at same rates as cigarette smokers); MARIJUANA AND MEDICINE ASSESSING THE
SCIENCE BASE 6, IOM (1999), available at http://medicalmarijuana.procon.org
/sourcefiles/IOM_Report.pdf (recommending marijuana not be smoked because of
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marijuana is widely debated; however, due to the low threshold of safety
data required for initial studies, marijuana would be safe enough to
progress to clinical studies.106 Upon IND approval for Phase I and Phase II
studies, the drug sponsor would further identify marijuana’s constituents,
continue to develop safety data, and begin to establish an effective dose of
marijuana.107
b.

IND Approval for Phase III Studies

IND approval for Phase III studies of marijuana will be much more
difficult to obtain because the sponsor is expected to provide more detailed
information of CMC and safety than when conducting a Phase I or Phase II
study.108 The FDA would require additional safety data in order to support
marijuana’s use among a much larger subject population size.109 As in
Phase I and Phase II, past human and animal studies will be considered;
however, further systematic toxicological evaluations could be needed to
supplement available knowledge on the general toxicity, teratogenicity,
mutagenicity, and carcinogenicity of the final marijuana product.110
Further detail regarding CMC data is required to ensure the
reproducibility of the substance.111 If the marijuana cannot be standardized
through manufacturing and controls, the Phase III trials are unlikely to
produce consistent data supporting the use of marijuana for the chosen
harmful effects of smoking).
106. See Deaths from Marijuana v. 17 FDA-Approved Drugs, PROCON,
http://medicalmarijuana.procon.org/view.resource.php?resourceID=000145 (last visited
Oct. 24, 2014) (demonstrating that there are fewer marijuana related deaths than
compared to many FDA approved drugs). But see Roxanne Khamsi, How Safe Is
Recreational Marijuana?, SCIENTIFIC AMERICAN (May 14, 2013), http://www.scientific
american.com/article/how-safe-recreational-marijuana/?page=2 (describing marijuana’s
negative effects to cognitive and motor function).
107. Drug Review Process, supra note 35 (stating Phase I testing focuses on safety,
and Phase II testing examines effectiveness).
108. See 21 C.F.R. § 312.22(b) (2014) (stating that information required for IND
approval is based on which Phase is being approved); BOTANICAL GUIDANCE, supra
note 33, at 27 (presenting guidance that more detailed information is required for Phase
III studies).
109. See BOTANICAL GUIDANCE, supra note 33, at 27 (requiring additional
toxicology data to support the product’s wider use within Phase III); Drug Review
Process, supra note 35 (explaining that in Phase III trials the subject group is generally
between several hundred and 3,000 people).
110. See BOTANICAL GUIDANCE, supra note 33, at 34-35 (depending on indication,
rout of administration and duration of recommended drug exposure, and other
requirements, nonclinical animal studies can vary).
111. See BOTANICAL GUIDANCE, supra note 33, at 27 (stressing the importance of
reproducibility in ensuring consistent data in well-controlled trials).
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condition.112 Standardizing marijuana requires producing batches of plants
with qualitatively and quantitatively comparable chemical constituents.
Batch to batch inconsistency will likely plague marijuana’s approval
because many strains of marijuana exist, each presenting a different variety
of characteristics.113 Additionally, environmental factors would create
further inconsistencies within each batch of marijuana.114 One could
imagine that Phase III studies would produce inconsistent data if a main
active constituent, say Tetrahydrocannabinol (THC), was found at different
levels per unit of marijuana.115 However, the solution to producing
consistent batches of marijuana could be the implementation of extensive
manufacturing controls.116 The sponsor achieves quality and consistency of
the final drug product by controlling the botanical source and adequate
blending, in combination with other downstream CMC controls on the
manufacturing processes.117 The final studies towards proving marijuana’s
effectiveness would commence upon the approval of marijuana’s IND for
Phase III.118

112. See id.
113. See Cannabis

Strain and Infused Product Explorer, LEAFLY,
http://www.leafly.com/explore (last visited Oct. 30, 2014) (documenting 1024 strains
of marijuana and general characteristics of each strain); cf. CENTER FOR DRUG
EVALUATION AND RESEARCH, CROSS DISCIPLINE TEAM LEADER REVIEW APPLICATION
NUMBER 202292ORIG1S000 7-12, (2012), available at http://www.accessdata.fda
.gov/drugsatfda_docs/nda/2012/202292Orig1s000CrossR.pdf (noting CMC issues
Fulyzaq, the second botanical drug ever approved, faced during NDA review).
114. See Frezza, supra note 90, at 1135 (quoting Suzanne D. McGuire, Comment,
Medical Marijuana: State Law Undermines Federal Marijuana Policy—Is the
Establishment Going to Pot?, 7 SAN JOAQUIN AGRIC. L. REV. 73, 74-75 (1997)).
115. See Karl W. Hillig & Paul G. Mahlberg, A CHEMOTAXONOMIC ANALYSIS OF
CANNABINOID VARIATION IN CANNABIS (CANNABACEAE), 91 AM. J. BOT. 966, 971-73
(June 2004), available at http://www.amjbot.org/content/91/6/966.full.pdf+html
(finding that various environmental and genetic factors determine the qualitative and
quantitative levels of cannabinoids within marijuana).
116. See BOTANICAL GUIDANCE, supra note 33, at 5 (suggesting the use of
manufacturing controls to ensure identity, purity, quality, strength, potency, and
consistency of botanical drugs).
117. Cf. BOTANICAL REVIEW APPLICATION NUMBER 21-202, CENTER FOR DRUG
EVALUATION AND RESEARCH (Oct. 31, 2006), available at http://www.acc
essdata.fda.gov/drugsatfda_docs/nda/2006/021902s000_botanicalr.pdf
(noting
recommendations for standardizing Veregen, the first botanical drug approved by the
FDA, during NDA review).
118. See Drug Review Process, supra note 35 (noting Phase III studies further test
safety and effectiveness among different patient populations and dosages).
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NDA Review

While the duration of clinical studies vary, the process of clinical testing
and NDA review for marijuana may take upwards of fifteen years to
complete.119 It will be up to marijuana’s sponsor to successfully show that
marijuana is safe and effective for treating a specific condition or
disease.120 There is no specific number or value that all drugs are
compared to when determining safety and effectiveness.121 Instead, the
FDA applies a risk-benefit analysis.122 Marijuana does not need to be more
effective than existing treatments for approval; marijuana only needs to be
proven effective through clinical testing.123 The FDCA does not clearly
define “safe,” and thus the FDA would base its determination on whether
the benefits of marijuana outweigh the potential risks.124 The technical
requirements are equally important, such as demonstrating that the
manufacturer can produce a standardized marijuana product and that the
clinical trials supporting marijuana’s effectiveness were conducted in
accordance to good clinical practice (GCP).125 If marijuana’s NDA is
119. How long does it take for a new drug to go through clinical trials?, CANCER
RESEARCH
UK,
http://www.cancerresearchuk.org/about-cancer/cancers-ingeneral/cancer-questions/how-long-does-it-take-for-a-new-drug-to-go-through-clinicaltrials (last visited Nov. 2, 2014) (explaining time it take to complete clinical trials
varies on type of disease, method of treatment, number of patients needed, length of
treatment, length of follow up period required, and any problems encountered).
120. 21 U.S.C. § 355(b)(1) (2012) (requiring NDA to be filed demonstrating a new
drug’s safety and effectiveness).
121. Brady Dennis, FDA’s ‘safe and effective’ drug approvals based on widely
varied
data,
study
finds,
WASH.
POST
(Jan.
21,
2014),
http://www.washingtonpost.com/national/health-science/fda-drug-approvals-based-onvaried-data-study-finds/2014/01/21/b12d0712-82be-11e3-80999181471f7aaf_story.html (discussing that FDA’s determination of safe and
effectiveness lacks uniformity, and that amount of data required for one drug’s
approval may not suffice for another’s).
122. See id.
123. See 21 C.F.R. § 314.105 (2014) (stating that the FDA has flexibility in
applying statutory standards, and uses its own scientific judgment to determine the kind
and quantity of data and information an applicant is required to provide for a particular
drug to meet the statutory standards); Robert J. Temple, Comparative Effectiveness
Research, FDA (Apr. 21, 2010), http://www.fda.gov/downloads/Drugs/NewsEvents
/UCM209270.pdf (stating that legislative history is clear, a new drug does not have to
be better than, or as good as existing treatments).
124. Structured Approach to Benefit-Risk Assessment in Drug Regulatory
Decision-Making,
FDA
(Feb.
2014),
available
at
http:/
/www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM32975
8.pdf (recognizing that all drugs have the ability to cause adverse effects, and thus are
examined on a benefit-risk assessment unique to each case).
125. See BOTANICAL GUIDANCE, supra note 33, at 33 (recommending that batch-to-
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submitted with careful consideration to FDA guidance and regulations then
the FDA’s decision should follow within ten months.126 Assuming
marijuana’s sponsor is able to show the necessary effectiveness and safety,
the CMC issues would still have to be worked out in order to assure
consistency of the product and, ultimately, approval from the FDA.127
Additionally, if marijuana were approved, only the specific strain of
marijuana that received an approved NDA would be available by
prescription.128 Any changes to the approved marijuana product would
require additional FDA premarket approval.129
B. Marijuana Regulated Under the Tobacco Provisions of the FDCA
Much like drugs, tobacco is regulated to minimize its harmful effects to
society; however, tobacco regulation is much less restrictive and provides
greater accessibility.130 Marijuana should be regulated like tobacco by
recognizing marijuana as a legal product that is only for adults, even

batch consistency be shown); Clinical Trial Guidance Documents, FDA,
http://www.fda.gov/RegulatoryInformation/Guidances/ucm122046.htm (last visited
Nov. 2, 2014) (providing documents on what the FDA considers to be good clinical
practice because how clinical trials are conducted is taken into consideration during
NDA review).
126. See Dhiren N. Shah, OBTAINING APPROVAL OF NEW DRUG APPLICATIONS AND
ABBREVIATED NEW DRUG APPLICATIONS FROM A CHEMISTRY, MANUFACTURING, AND
CONTROLS PERSPECTIVE 406, AVENTIS PHARMACEUTICALS (2005), available at http://
www.slideshare.net/priyankagangarapu/nda-anda-approval (noting from a technical
regulatory perspective, if all the work is done properly as described in sections a-h, the
NDA submission should become fairly easy); Drug Review Process, supra note 35
(stating that 90% of NDA applications are acted upon within 10 months).
127. See 21 U.S.C. § 355(d) (2013) (stating that a NDA may be refused if the
methods used, and the facilities and controls used for, the manufacture, processing, and
packing of such drug are inadequate to preserve its identity, strength, quality, and
purity).
128. See § 353(b) (requiring drugs that present potential safety issues be only
prescribed by a licensed practitioner, and only be dispensed by a pharmacist).
129. See GUIDANCE FOR INDUSTRY CHANGES TO AN APPROVED NDA OR ANDA,
FDA
(Apr.
2004),
available
at
http://www.fda.gov/downloads/drugs/
guidancecomplianceregulatoryinformation/guidances/ucm077097.pdf
(explaining
changes to an approved drug that effect its identity, strength, quality, purity, or potency
must be submitted to FDA for approval before further marketing).
130. See, e.g., § 387f (d) (preventing the promulgation of rules that would require a
prescription for tobacco). But see Drugs Applications for Over-the-Counter (OTC)
Drugs, FDA, http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredeve
lopedandapproved/approvalapplications/over-the-counterdrugs/default.htm (last viewed
Dec. 4, 2014) (explaining OTC drugs are safe and effective for use by general public
without seeking treatment by a health professional).
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though it poses potential health risks.131 The Secretary of HHS would also
possess the authority to promulgate rules, upon Congress specifically
giving the FDA authority over marijuana, appropriate to minimizing the
potential risks of marijuana, while still allowing society to access it with
great ease as compared to drug regulations.132 The FDA would regulate
almost every aspect of the marijuana industry, including manufacturing,
labeling, advertising, and sale.133
The manufacturing of marijuana could be regulated in multiple ways
similar to how tobacco is regulated, which would ensure that consumers get
the safest product possible.134 Manufactures would have to disclose all
components of the marijuana products, and the FDA could regulate the
amounts of each component, such as THC.135 Additionally, the FDA
would have the authority to impose strict quality standards to assure
nothing is introduced into the marijuana that could present additional risks
to the consumer, such as intentional or unintentional chemical additives.136
Restrictions on labeling and advertisement would allow the FDA to
control the information consumers get about marijuana, as well as which
consumers are targeted with that information.137 Like the FDA’s goal in
regulating tobacco, the goal with marijuana will be ensuring people are
aware of its risks, and preventing marijuana use among minors.138 Labeling
131. See TCA Overview, supra note 49 (explaining a goal of tobacco regulation is
to prevent use of a potentially harmful substance before fully understanding risks).
132. See § 387f (giving HHS Secretary authority to create rules promoting public
health with regards to tobacco).
133. See generally § 387 (imposing regulations upon tobacco sales, advertising,
labeling, and manufacturing).
134. See § 387d (b) (requiring data submissions relating to research activities of
tobacco manufacturer); § 387e (listing specific annual registration requirements for
manufacturers, including facilities and products); § 387i (requiring manufacturers to
keep and present specified records on request); § 387t(2) (allowing promulgation of
rules related to inspection).
135. See § 387d (a)(1) (requiring disclosure of tobacco product compounds); § 387g
(stating tobacco product standards); Drug Facts: Marijuana, NATIONAL INSTITUTE ON
DRUG
ABUSE
(January
2014),
http://www.drugabuse.gov/publications/drugfacts/marijuana (arguing increase of THC
in marijuana creates adverse effects).
136. See § 387b (defining tobacco products that are filthy, poisonous, or deleterious
as adulterated); § 387h (explaining FDA’s recall authority of misbranded or adulterated
products).
137. See TCA Overview, supra note 49 (banning tobacco advertisements within
1,000 feet of a school or playground, as well as banning tobacco advertisement from
sporting and entertainment events).
138. See id. (explaining a goal of tobacco regulation is to prevent use of a
potentially harmful substance before fully understanding risks).
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restrictions would effectively eliminate manufacturers from marketing their
products as safe, and would impose visibility requirements on any health
Marijuana
warnings the Secretary of HHS deems necessary.139
manufacturers under such a regime could not market their products as safe
because marijuana has side effects, including diminished cognitive
performance and many of the same respiratory illnesses associated with
smoking tobacco.140
Furthermore, sales regulations on marijuana could reduce access to the
substance for minors.141 The Secretary of HHS could impose an age
restriction on sales of marijuana.142 An age restriction would mean that no
business, in any state, could sell marijuana to an individual under a specific
age.143 Equally important, the Secretary is restricted from making the
minimum age greater than eighteen years old for tobacco, and thus still
maintaining access for the adult population.144 By using the tobacco model
as the framework for marijuana regulation, a minimum age should be
imposed, but experts may want to impose a different age than that of
tobacco because of marijuana’s effects on brain development.145
The tobacco provisions that are most distinguishable from the drug
model are those that limit the FDA’s authority to promulgate rules that
would severely restrict access to tobacco, e.g., not allowing the FDA to
restrict face-to-face sale, to ban certain categories of tobacco, or to require
prescriptions to purchase tobacco.146 These limitations decrease the FDA’s

139. See § 387c (stating a tobacco product that does not have proper labeling or is
misleading will be considered misbranded); § 387k (restricting use of “reduced risk”
terms on labeling, such as light, low, or mild); § 387h (explaining that the FDA has
authority to recall a product if it is misbranded).
140. See Drug Facts: Marijuana, supra note 135 (finding marijuana smoke to be a
lung irritant causing daily cough and phlegm production, more frequent acute chest
illness, and a heightened risk of lung infections).
141. See TCA Overview, supra note 49.
142. Cf. § 387f(d) (allowing promulgation of restrictions on sale and distribution of
a tobacco products).
143. See id. (providing authority to promulgate rules appropriate for the protection
of the public health).
144. See § 387f (d)(3)(A)(ii) (limiting the Secretary’s ability to establish a
minimum age older than 18 year old for tobacco products).
145. See Drug Facts: Marijuana, supra note 135 (explaining that heavy marijuana
during adolescent years causes a decline in IQ); Michael Martinez, 10 things to know
about nation’s first recreational marijuana shops in Colorado, CNN (Jan. 1, 2014),
http://www.cnn.com/2013/12/28/us/10-things-colorado-recreational-marijuana/
(requiring marijuana buyers to be 21 or older in Colorado).
146. See generally § 387f (d)(3)(A) (detailing restrictions on the Secretaries rule
making authority).
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authority enough to ensure access to tobacco products, and thus would
provide easier access to marijuana, especially compared to marijuana
regulated under the drug provisions.147 If marijuana were regulated with
these same access-promoting provisions as tobacco, it would remain
regulated, but not to the point of being regulated out of the market as would
happen if marijuana were regulated as a drug.148
1. Premarket Approval for “New Tobacco Products” Could Not Be Used
to Regulate New Marijuana Products Because the Analysis Is based on
Previously Marketed Products
FDCA provides that “new tobacco products” must be pre-approved by
the FDA before being marketed.149 This provision would not work with
marijuana because the premarket review compares the new tobacco product
to tobacco products that are currently being commercially marketed.150 A
provision comparing new products to already marketed products works for
tobacco because the industry is well established. Tobacco products have
been marketed for hundreds of years, so there are standards to compare the
new products to.151 Marijuana, on the other hand, is not legally sold in the
United States, so there are no existing products to base a new product
determination from.152 Since the FDA lacks the ability to compare new
marijuana products to currently marketed products, the regulations
requiring premarket approval for new marijuana products would not
work.153 Nevertheless, a solution for premarket review of marijuana would
require further research, because without premarket review marijuana
would be less regulated then tobacco.154 Possible solutions that should be
explored include prospective legislation that creates a predicate marijuana
147. See id. (providing limits to rule making as not to challenge tobacco’s
recreational use).
148. Compare § 387f (restricting rule promulgation authority to insure access) with
§ 355 (requiring an extensive premarket approval process before a new drug can be
marketed).
149. See § 387j (defining tobacco products not marketed before February 15, 2007,
or existing tobacco products that are modified as new tobacco products).
150. See id. (comparing materials, ingredients, design, composition, heating source,
and other features).
151. See § 387j (2)(A)(i)(I) (exempting product that are substantially equivalent to
traditional tobacco products from new product requirements).
152. § 812 (placing marijuana in the Schedule I category of illicit drugs, and thus
making it a Federal crime to sell marijuana in the United States).
153. See § 387j (defining tobacco products not marketed before February 15, 2007,
or existing tobacco products that are modified as new tobacco products).
154. See id. (requiring new tobacco product, that are not substantially equivalent to
predicate tobacco product, to undergo premarket review).
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product once marijuana has been commercially marketed for a couple of
years or a mandatory premarket review that is based on a new standard.155
The drug model and tobacco model both provide viable regulation
schemes that could be used to regulate marijuana.156 A drug model would
provide the greatest control over marijuana, requiring thorough premarket
review in order to demonstrate safety and effectiveness.157 Premarket
review for a drug is very costly and time consuming, and ultimately may
not result in approval.158 Additionally, the drug model would limit
marijuana to medicinal use only, which would require people to obtain a
prescription for lawful use, thereby restricting access.159 The tobacco
model is in some ways like the drug model, providing regulation over
manufacturing, labeling, advertising, and sale.160 However, the tobacco
model would better handle the variety of marijuana strains by not requiring
production to be limited to a single standardized product, unlike the drug
model that requires one uniform product.161 The tobacco model would
provide less control over marijuana, creating a balance between access and
oversight by recognizing marijuana as a legal product, for adults, that poses
potential health risks.162 Although the tobacco model would best
accommodate the recreational use of marijuana, it would not be able to
formally recognize valid medicinal uses of marijuana.163 Any claim from a
manufacturer that its marijuana product could be used to treat or mitigate
some condition would instantly make that marijuana product an

155. This comment recognizes that some degree of premarket review would be
critical, however, the creation of a new premarket review exclusively for marijuana is
outside the purview of this comment.
156. See generally §§ 301 et seq. (providing statutes for the regulation of drugs and
tobacco).
157. See generally § 355 (requiring the sponsor of any new drugs to demonstrate
safety and effectiveness through clinical trials before commercially marketing the
product).
158. See Herper, supra note 40 (explaining a single clinical trial can cost up to $100
million).
159. See § 353(b) (requiring drugs with potential safety issues be prescribed by a
licensed practitioner).
160. See generally § 387 (imposing regulations upon tobacco sales, advertising,
labeling, and manufacturing).
161. See BOTANICAL GUIDANCE, supra note 33, at 11-12 (recommending sponsor
produce batch-to-batch consistency).
162. See TCA Overview, supra note 49 (explaining a goal of tobacco regulation is
to prevent use of a potentially harmful substance before fully understanding risks).
163. See § 321(g) (stating that claims to mitigate, treat, or prevent disease makes a
product a drug).
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unapproved new drug.164 Regardless, physicians could still recommend a
marijuana product for purposes of treatment, even if that product is not
formally recognized for treating said condition.165 Nevertheless, the
tobacco model provides enough regulation to minimize the risks marijuana
may present, such as pulmonary disease and access for minors.166 The
major difference between the drug model and tobacco model is that the
tobacco model would provide explicit statutory language preventing FDA
from issuing regulations that would greatly inhibit access to marijuana.167
A tobacco model would allow for distribution similar to cigarettes or
alcohol.168 Because tobacco is a botanical product, the tobacco model
would better incorporate marijuana, allowing the inconsistencies and
variations that the drug model is not meant to handle.169
IV. CONCLUSION
The majority opinion in the United States favors the legalization of
marijuana.170 A significant number of states have legalized marijuana for
medicinal use, and a growing number of states have legalized marijuana for
recreational use.171 When the federal government decides to follow the
majority and legalize marijuana to some degree, they will have various
models of regulation to choose from.172 The drug model provides the best
regime for marijuana if legalized purely for medicinal purposes.173 Even
164. See § 321(p) (stating that any drug without an approved NDA is a new drug).
165. Cf. “Off-Label” and Investigational Use of Marketed Drugs, Biologics, and

Medical Devices – Information Sheet, FDA, http://www.fda.gov/RegulatoryInformat
ion/Guidances/ucm126486.htm (last visited Dec. 5, 2014) (recognizing physicians
ability to prescribe medicine for off-label uses).
166. See § 387f (giving HHS Secretary authority to create rules promoting public
health with regards to tobacco).
167. See generally § 387f (d) (detailing restrictions on the Secretaries rule making
authority).
168. See id. (providing that face-to-face sales cannot be eliminated, nor can a
prescription be required to by tobacco)
169. See BOTANICAL GUIDANCE, supra note 33, at 2 (defining botanical product as a
finished product that contains vegetable matter).
170. See Swift, supra note 1 (discussing that 58% of Americans favor legalization
of marijuana).
171. See Marijuana Map, supra note 8 (showing 23 state and the District of
Columbia have legalized marijuana).
172. See generally §§ 301 et seq. (providing FDA with authority to regulate a
variety of products accounting for about 25 cents of every dollar spent by consumers in
the United States).
173. See § 355 (requiring new drugs to be generally recognized as safe and effective
my experts).

https://digitalcommons.wcl.american.edu/jgspl/vol23/iss4/4

24

Erly: High Times: Is The Federal Legalization of Marijuana Next?

2015]

HIGH TIMES

683

though marijuana would have difficulties obtaining an NDA due to
standardization issues, the drug model’s safe and effective standard would
ensure patients get the best marijuana product for treating their condition.174
However, if recreational use of marijuana is legalized, then the tobacco
model would be far superior, providing enough regulation to mitigate risk
but maintain access to marijuana, while also avoiding standardization
issues.175 Nevertheless, the current FDA regime could incorporate both
models by allowing the tobacco model to regulate recreational use, while
still affording manufacturers the opportunity to submit NDAs if they wish
to make drug claims or have their products covered by insurance.176
Current medical marijuana markets include different strains of marijuana
that are supposedly better for particular conditions.177 A mature medical
marijuana market almost certainly will not be one size fits all.178 Producers
will want to customize their products and make claims promoting specific
products for specific uses.179 The legalization of marijuana is coming and
the FDA has the means to regulate its distribution.180

174. See BOTANICAL GUIDANCE, supra note 33, at 11-12 (recommending a single
formulation and a single dosage form be used throughout different states of the clinical
trials unless impossible).
175. See TCA Overview, supra note 49 (explaining a goal of tobacco regulation is
to prevent use of a potentially harmful substance before fully understanding risks).
176. See MEDICARE DRUG COVERAGE UNDER MEDICARE PART A, PART B, PART C,
& PART D, HHS (Jan. 2014), available at http://www.cms.gov/Outreach-andEducation/Outreach/Partnerships/downloads/11315-P.pdf (requiring a medication to be
FDA approved in order for Medicare Part D to cover it).
177. See How Do You Know What Medical Marijuana Strain Is Right for You?,
UNITED PATIENTS GROUP (Jan. 31, 2012), http://www.unitedpatientsgroup.com/bl
og/2012/01/31/how-do-you-know-which-medical-marijuana-strain-is-right-for-you/.
178. Cf. Amanda Reiman, The Fallacy of a One Size Fits All Cannabis Policy, 35
HUMBOLDT JOURNAL OF SOCIAL RELATIONS 104, 118 (2013), available at
http://www2.humboldt.edu/hjsr/docs/fwhjsrparagraph/Issue%2035%20Seventh%20Art
icle%20Reiman.pdf (acknowledging that marijuana is a complex plant with many
forms and uses).
179. See, e.g., Strain Guide, MEDICAL MARIJUANA STRAINS, http://www.medica
lmarijuanastrains.com/strain-guide/ (last viewed Apr. 22, 2015) (creating a search
index for medical marijuana based on illness and desired effect).
180. See Swift, supra note 1 (finding that 58% of Americans favor legalizing
marijuana).
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